On April 23, 2015, Noven Pharmaceuticals, Inc. and Hisamitsu Pharmaceuticals Co., Inc. (“Plaintiffs”) filed a complaint against Mylan, Inc., Mylan Pharmaceuticals, Inc., and Mylan Technologies, Inc. (“Defendants”) asserting infringement of U.S. Patent Nos. 6,841,716 (“the ‘716 Patent”) and 8,231,906 (“the ‘906 Patent”). The ‘716 Patent and the ‘906 Patent are assigned to the Plaintiffs and generally relate to transdermal drug delivery systems, including the transdermal delivery of estrogen. The Plaintiffs are asserting that the Defendants are infringing the ‘716 Patent and the ‘906 Patent by their filing of an ANDA seeking approval to market and sell a generic Estradiol Transdermal System. The case remains pending and is captioned 1-15-cv-00328.
By: Jacqueline A. DiRamio